| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44e0905262f429c7590b40df8448c0c5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4458
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2018-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f3e80d21837335503e0a01883c20a23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af5ce144e4faeb67b8726b99ed2718ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08a49428fa9a86339350aaea98d07a4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b0d1c7b48c0466196700bf995e487c3 |
| publicationDate |
2020-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111465390-A |
| titleOfInvention |
Modified release abuse prevention dosage form |
| abstract |
The present invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of the pharmacologically active compound is contained in a plurality of immediate release granules providing immediate release of the pharmacologically active compound; wherein another portion of the pharmacologically active compound Included in at least one controlled release granule that provides controlled release of the pharmacologically active compound; and wherein each of the immediate release granules and/or the at least one controlled release granule has a crushing strength of at least 300N. |
| priorityDate |
2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |